KANNALIFE
DEAD

Serial Number

86034690

Owner

KannaLife Sciences, Inc.

Attorney

Brad M. Behar

Filing Date

Aug 12, 2013

Add to watchlist:

No watchlists yet
View on USPTO

KANNALIFE Trademark

Serial Number: 86034690

KANNALIFE is a trademark filed by KannaLife Sciences, Inc. on August 12, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KannaLife Sciences, Inc. (16 trademarks)

363 West Hills Road
West Hills, NY 11743

Entity Type: 03

Trademark Details

Filing Date

August 12, 2013

Registration Date

Not Registered

Published for Opposition

August 12, 2014

Goods & Services

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Inhalers filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents for epidermis; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment and prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations, namely, elixirs for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Sunburn preparations for pharmaceutical purposes; Syringes sold filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Syrups for pharmaceutical purposes for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Therapeutic pharmaceutical for the treatment of Oxidative Stress Related and Neurodegenerative Diseases

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating Oxidative Stress Related and Neurodegenerative Diseases; Chemical additives for use in the manufacture of naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Emollient used as an ingredient in the manufacture of cosmetics, toiletries, and pharmaceuticals

Conducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of Oxidative Stress Related and Neurodegenerative Diseases

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 11, 2015 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 11, 2015 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 7, 2014 NOAM
ASSIGNED TO EXAMINER
Aug 13, 2014 DOCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 12, 2014 NPUB
PUBLISHED FOR OPPOSITION
Aug 12, 2014 PUBO
ASSIGNED TO EXAMINER
Aug 11, 2014 DOCK
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 23, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 8, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 7, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 10, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2014 CRFA
ASSIGNED TO LIE
Jun 4, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 21, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 27, 2013 GNRN
NON-FINAL ACTION E-MAILED
Nov 27, 2013 GNRT
NON-FINAL ACTION WRITTEN
Nov 27, 2013 CNRT
ASSIGNED TO EXAMINER
Nov 27, 2013 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Aug 21, 2013 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2013 NWOS
NEW APPLICATION ENTERED
Aug 15, 2013 NWAP